

INFORMATION DISCLOSURE CITATION

Form PTO-1449 (Modified)

(Use several sheets if necessary)

ATTY. DOCKET NO.
BEAR-004SERIAL NO.
09/642,609

APPLICANT

Kumagai et al.

FILING DATE
August 17, 2000GROUP
1614 1653

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
AM	AA 5,665,700	09/09/1997	Cho et al.	514	2	RECEIVED
AM	AB 5,981,475	11/09/1999	Reynolds	514	6	DEC 04 2000
AM	AC 6,028,053	02/22/2000	Van der Geer et al.	514	7	

FOREIGN PATENT DOCUMENTS

TECH CENTER 1600/2900

Document Number	Date	Country	Class	Subclass	Translation
AM AD WO 99/22743	05/14/1999	PCT			YES No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AM	AE	Anderson et al. (1972), "Characterization of Three Sequential Polypeptides containing Glycine." <i>J. Mol. Biol.</i> , Vol. 67:459-468.
↑	AF	Andress et al. (1987), "Osteomalacia and Aplastic Bone Disease in Aluminum-Related Osteodystrophy." <i>Journal of Clinical Endocrinology and Metabolism</i> , Vol. 65(1):11-16.
	AG	Andress et al. (1989), "Intravenous Calcitriol in the Treatment of Refractory Osteitis Fibrosa of Chronic Renal Failure." <i>The New England Journal of Medicine</i> , Vol. 321(5): 274-279.
	AH	Delmez et al. (1992), "Hyperphosphatemia: Its Consequences and Treatment in Patients with Chronic Renal Disease." <i>American Journal of Kidney Diseases</i> , Vol. 19 (4): 303-317
	AI	DeTar et al. (1967), "Sequence Peptide Polymers. III. Poly Asp(OH)-Ser(H)-Gly and Other Serine-Containing Polymers." <i>Journal of the American Chemical Society</i> , Vol. 89(12):3039-3045.
	AJ	Emmett et al. (1991), "Calcium Acetate Control of Serum Phosphorus in Hemodialysis Patients." <i>American Journal of Kidney Diseases</i> , Vol. 17(5):544-550
	AK	Faugere et al. (1986), "Loss of bone resulting from accumulation of aluminum in bone of patients undergoing dialysis." <i>The Journal of Laboratory and Clinical Medicine</i> , Vol. 107(6):481-487.
	AL	Felsenfeld et al. (1999), "Phosphorus, Regulation of Plasma Calcium, and Secondary Hyperparathyroidism: A Hypothesis to Integrate a Historical and Modern Perspective." <i>J. Am. Soc. Nephrol.</i> , Vol. 10:878-890.
	AM	Reichel et al. (1989), "The Role of the Vitamin D Endocrine System in Health and Disease." <i>The New England Journal of Medicine</i> , Vol. 320(15):980-991
✓	AN	Slatopolsky et al. (1973), "The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease." <i>Kidney International</i> , Vol. 4:141-145.
AM	AO	Slatopolsky et al. (1986), "Alternative Phosphate Binders in Dialysis Patients: Calcium Carbonate." <i>Seminars in Nephrology</i> , Vol. 6(4) supp 1: 35-41.


EXAMINER

Abdel A. Mohamed

DATE CONSIDERED

4/11/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. BEAR-004	SERIAL NO. 09/642,609
		APPLICANT Kumagai et al.	
		FILING DATE August 17, 2000	GROUP 1614-1653
	AP	Ward et al. (1978), "Osteomalacic Dialysis Osteodystrophy: Evidence for a Water-borne Aetiological agent, probably aluminum." <i>The Lancet</i> , Vol. 1(8069): 841-845.	


F:\forms\word 2k forms\form PTO-1449.doc



RECEIVED

DEC 04 2000


TECH CENTER 1600/2900

EXAMINER 	DATE CONSIDERED 4/11/04
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Please type a plus sign (+) inside this box →



COPY OF PAPERS
ORIGINALLY FILED



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Applicant Number	09/642,609	
			Filing Date	August 17, 2000	
			First Named Inventor	KUMAGAI ET AL.	
			Group Art Unit	1614-1653	
Examiner Name	To Be Assigned				
Sheet	1	of	<<TEXT>>	Attorney Docket Number	BEAR004

RECEIVED
 FEB 25 2001
 TECH CENTER 1600/1900

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear CLASS Sub class
		Number	Kind Code ² (if known)			
AK		5,837,674		Kumagai et al.	11/17/98	514 7
AK		5,527,881		Poblet et al.	06/18/96	530 307

FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear T ²
		Office ³	Number ⁴	Kind Code ⁵ (if known)			



OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²

Examiner Signature	Abdel A. Mohamed	Date Considered	4/11/04
--------------------	------------------	-----------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.